ALW-II-49-7
目录号 : GC68647ALW-II-49-7是一种选择性的EphB2激酶抑制剂，其IC50值为40nM。
Cas No.:1135219-23-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an IC50 value of 40nM[1]. ALW-II-49-7 is also characterized as a DDR1 inhibitor(IC50 =12.4nM) and a DDR2 inhibitor(IC50=18.6nM)[2]. EphB2 kinase, a receptor tyrosine kinase belonging to the Eph family, is involved in various cellular signal transduction processes, including cell migration, adhesion, differentiation and proliferation[3]. DDR1 and DDR2 are also receptor tyrosine kinases that are widely expressed on the cell surface, activate downstream signaling pathways by recognizing collagen in the extracellular matrix, and regulate cell adhesion, migration, proliferation, and differentiation[4]. ALW-II-49-7 is commonly used in research of cancer and fibrosis[5][6].
In vitro, ALW-II-49-7 (0.01-10μM; 1h) inhibit the activity of EphB2 kinase in U87 glioblastoma cells[1]. In HEK293T (293T) cells transfected with wild-type DDR2, ALW-II-49-7 (0.1-10μM; 16h) decreases DDR2 phosphorylation in a dose-dependent manner[2]. ALW-II-49-7(3μM; 24h) significantly inhibited DDR1 phosphorylation induced by collagen I and reduced the synthesis of collagen IV in HEK293 cell lines and DDR1 knockout mesangial cells[7].
References:
[1] Choi Y, Syeda F, Walker JR, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009;19(15):4467-4470.
[2] Terai H, Tan L, Beauchamp EM, et al. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chem Biol. 2015;10(12):2687-2696.
[3] Liu W, Yu C, Li J, Fang J. The Roles of EphB2 in Cancer. Front Cell Dev Biol. 2022;10:788587.
[4] Agarwal G, Smith AW, Jones B. Discoidin domain receptors: Micro insights into macro assemblies. Biochim Biophys Acta Mol Cell Res. 2019;1866(11):118496.
[5] Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165-180.
[6] Ling S, Kwak D, Kim KK. Inhibition of discoidin domain receptor 2 reveals kinase-dependent and kinase-independent functions in regulating fibroblast activity. Am J Physiol Lung Cell Mol Physiol. 2023;325(3):L342-L351.
[7] Jeffries DE, Borza CM, Blobaum AL, Pozzi A, Lindsley CW. Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy. ACS Med Chem Lett. 2019;11(1):29-33.
ALW-II-49-7是一种选择性的EphB2激酶抑制剂，其IC50值为40nM[1]。ALW-II-49-7也是DDR1抑制剂（IC50 = 12.4nM）和DDR2抑制剂 ( IC50 = 18.6nM)[2]。EphB2激酶是Eph家族的受体酪氨酸激酶，参与多种细胞信号转导过程，包括细胞迁移、黏附、分化和增殖[3]。DDR1和DDR2也是受体酪氨酸激酶，它们广泛表达在细胞表面，通过识别细胞外基质中的胶原蛋白激活下游信号通路，调节细胞黏附、迁移、增殖和分化[4]。ALW-II-49-7常用于癌症和纤维化的研究[5][6]。
在体外实验中，ALW-II-49-7（0.01-10μM；1小时）能够抑制U87胶质母细胞瘤细胞中EphB2激酶的活性[1]。在转染了野生型DDR2的HEK293T（293T）细胞中，ALW-II-49-7（0.1-10μM；16小时）以剂量依赖的方式降低DDR2的磷酸化水平[2]。在HEK293细胞和DDR1基因敲除系膜细胞中，ALW-II-49-7（3μM；24小时）显著抑制了胶原蛋白I诱导的DDR1磷酸化，并减少了胶原蛋白IV的合成[7]。
| Cell experiment [1]: | |
Cell lines | HEK293T (293T) cells |
Preparation Method | HEK293T (293T) cells were cultured in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum, 20mM HEPES buffer, 100U/ml penicillin, 100μg/ml streptomycin, and 100μg/ml gentamicin. DDR2 was transiently expressed in 293T cells by the pCMV6 expression vector. Cells were treated with depicted concentrations of ALW-II-49-7(0.1-10μM) for 16h. Cell lysates were immunoprecipitated with anti-DDR2, followed by Western blotting with anti-DDR2 or antiphosphotyrosine. |
Reaction Conditions | 0.1-10μM; 16h |
Applications | ALW-II-49-7 decreases DDR2 phosphorylation in a dose-dependent manner. |
References: | |
| Cas No. | 1135219-23-6 | SDF | Download SDF |
| 分子式 | C21H17F3N4O2 | 分子量 | 414.38 |
| 溶解度 | DMSO : 100 mg/mL (241.32 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4132 mL | 12.0662 mL | 24.1324 mL |
| 5 mM | 0.4826 mL | 2.4132 mL | 4.8265 mL |
| 10 mM | 0.2413 mL | 1.2066 mL | 2.4132 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet